UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Nature reviews. Rheumatology, ISSN 1759-4790, 09/2017, Volume 13, Issue 9, pp. 561 - 568
Life Sciences & Biomedicine | Rheumatology | Science & Technology | United States | Arthritis, Gouty - diagnosis | Humans | Hyperuricemia - diagnosis | Gout - diagnosis | Gout - drug therapy | Male | Treatment Outcome | Hyperuricemia - drug therapy | Gout Suppressants - therapeutic use | Arthritis, Gouty - drug therapy | Societies, Medical | Crystal Arthropathies - diagnosis | Internationality | Crystal Arthropathies - therapy | Gout Suppressants - pharmacology | Female | Disease Management | Practice Guidelines as Topic | Hyperuricemia | Physicians | Gout | Crystals | Discordance | Clinical trials | Rheumatism | Uric acid | Index Medicus
Journal Article
Arthritis care & research (2010), ISSN 2151-464X, 03/2019, Volume 71, Issue 3, pp. 427 - 434
Life Sciences & Biomedicine | Rheumatology | Science & Technology | Uric Acid - analysis | Delphi Technique | Crystal Arthropathies - diagnosis | Humans | Hyperuricemia - diagnosis | Gout - diagnosis | Crystal Arthropathies - classification | Hyperuricemia - classification | Gout - classification | Consensus | Hyperuricemia | Etiology | Gout | Crystals | Standardization | Arthritis | Agreements | Uric acid | Bone imaging | Face | Index Medicus | nomenclature | urate | terminology | gout | Rheumatology and Autoimmunity | Reumatologi och inflammation
Journal Article
The New England journal of medicine, ISSN 0028-4793, 03/2018, Volume 378, Issue 13, pp. 1200 - 1210
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Double-Blind Method | Humans | Middle Aged | Gout - drug therapy | Male | Gout Suppressants - adverse effects | Cause of Death | Febuxostat - adverse effects | Gout Suppressants - therapeutic use | Allopurinol - therapeutic use | Cardiovascular Diseases - complications | Febuxostat - therapeutic use | Gout - complications | Allopurinol - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Cardiovascular Diseases - chemically induced | Care and treatment | Safety and security measures | Allopurinol | Cardiac patients | Gout | Dosage and administration | Drug therapy | Heart failure | Myocardial infarction | Cerebral infarction | Heart attacks | Mortality | Clinical trials | Cardiovascular disease | Angina | Xanthine | Metabolism | Angina pectoris | Patients | Evidence-based medicine | Medicine | Motivation | Rheumatism | Xanthine oxidase | Death | Cardiovascular diseases | Drug dosages | Chronic illnesses | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 15, pp. 1417 - 1427
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Risk | Bone Remodeling - drug effects | Alendronate - therapeutic use | Incidence | Spinal Fractures - prevention & control | Female | Drug Therapy, Combination | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Alendronate - adverse effects | Bone Density - drug effects | Alendronate - pharmacology | Least-Squares Analysis | Aged | Cardiovascular Diseases - chemically induced | Fractures, Bone - prevention & control | Treatment outcome | Care and treatment | Fractures | Growth | Analysis | Monoclonal antibodies | Bones | Research | Jaw | Femur | Vertebrae | Immunoglobulins | Inhibitor drugs | Osteonecrosis | SOST protein | Bisphosphonates | Hip | Post-menopause | Bone resorption | Osteoporosis | Alendronic acid | Bone growth | Bone density | Drug therapy | Osteogenesis | Index Medicus | Abridged Index Medicus | randomized-trial | metaanalysis | disease | postmenopausal women | strength | bone-mineral density | Klinisk medicin | vertebral fractures | sclerosteosis | Clinical Medicine | aorta | risk
Journal Article
The journal of clinical endocrinology and metabolism, ISSN 0021-972X, 05/2018, Volume 103, Issue 8, pp. 2949 - 2957
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Osteoporosis | Alendronate | Drug therapy | Testing | Vertebrae | Risk reduction | Risk | Bisphosphonates | Hip | Post-menopause | Incidence | Alendronic acid | Fractures | Biocompatibility | Bone mineral density | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
Nature reviews. Endocrinology, ISSN 1759-5029, 01/2014, Volume 10, Issue 10, pp. 592 - 602
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Osteoporosis - mortality | Randomized Controlled Trials as Topic - methods | Humans | Osteoporosis - diagnosis | Bone Density Conservation Agents - therapeutic use | Osteoporosis - drug therapy | Fractures, Bone - diagnosis | Fractures, Bone - mortality | Animals | Hip Fractures - drug therapy | Diphosphonates - therapeutic use | Hip Fractures - mortality | Hip Fractures - diagnosis | Fractures, Bone - drug therapy | Osteoporosis | Complications and side effects | Fractures | Risk factors | Index Medicus
Journal Article
Annals of the rheumatic diseases, ISSN 0003-4967, 06/2020, Volume 79, Issue 6, pp. 685 - 699
DMARDs (biologic) | treatment | DMARDs (synthetic) | Immunology | Rheumatology | economic evaluations | Biochemistry, Genetics and Molecular Biology(all) | rheumatoid arthritis | Immunology and Allergy | Life Sciences & Biomedicine | Science & Technology | Drugs | Costs | Glucocorticoids | Clinical trials | Leflunomide | Regulatory approval | Risk factors | Infliximab | Etanercept | Janus kinase | Remission | Sulfasalazine | Methotrexate | Medical personnel | Task forces | Biological products | Autoantibodies | Rituximab | Regions | Tumor necrosis factor-α | Patients | Rheumatoid arthritis | Monoclonal antibodies | Tumors | Index Medicus | Medicin och hälsovetenskap
Journal Article